期刊文献+

卡马西平联合丙戊酸钠治疗额叶癫痫对减轻脑损伤的作用

Effect of Carbamazepine Combined with Valproate Sodium in the Treatment of Frontal Lobe Epilepsy on Brain Injury
原文传递
导出
摘要 目的探讨卡马西平联合丙戊酸钠治疗额叶癫痫对减轻脑损伤的作用。方法选取2015年10月至2019年6月沈阳市第四人民医院收治的76例额叶癫痫患者作为研究对象,按照随机数字表法分为对照组与观察组,每组38例。对照组患者予以卡马西平治疗,观察组在对照组基础上采用丙戊酸钠治疗,比较两组患者治疗前后P300潜伏期、焦虑程度和抑郁程度、癫痫发作次数和发作时间。结果治疗前,两组患者P300潜伏期比较,差异无统计学意义(P>0.05);治疗后,两组P300潜伏期下降,且观察组P300潜伏期低于对照组,差异有统计学意义(P<0.05)。治疗前,两组患者焦虑自评量表(SAS)与抑郁自评量表(SDS)评分比较,差异无统计学意义(P>0.05);治疗后,两组SAS与SDS评分下降,且观察组SAS和SDS评分低于对照组,差异有统计学意义(P<0.05)。治疗前,两组患者癫痫发作次数、发作时间比较,差异无统计学意义(P>0.05);治疗后,两组患者癫痫发作次数减少,发作时间缩短,且观察组优于对照组,差异有统计学意义(P<0.05)。结论卡马西平联合丙戊酸钠治疗额叶癫痫,可发挥协同作用,抑制病灶异常放电,改善患者焦虑、抑郁症状,缓解临床表现,降低癫痫发作频率,减轻脑损伤。 Objective To analyze the effects of carbamazepine combined with valproate sodium in the treatment of frontal lobe epilepsy on the alleviation of brain injury. Methods A total of Seventy-six patients with frontal lobe epilepsy admitted to the 4 th People’s Hospital of Shenyang from October 2015 to June 2019 were selected as research objects and were divided into a control group and an observation group according to the random number table method, with thirty-eight cases in each group. The control group was given carbamazepine orally and the observation group was combined with valproate orally plus carbamazepine. P300 incubation period, level of anxiety and depression, the number and duration of seizures before and after treatment were compared between the two groups. Results Before treatment, the incubation period of P300 in the two groups was compared, the difference was not statistically significant(P>0.05);after treatment, the incubation period of P300 decreased. And the P300 latency of the observation group was lower than that of the control group, the difference was statistically significant(P<0.05). Before treatment, there was no statistically significant difference in self-rating anxiety scale(SAS) and self-rating depression scale(SDS) scores between the two groups(P>0.05);after treatment, the SAS and SDS scores of the two groups decreased, and the SAS and SDS scores of the observation group were lower than those of the control group, the difference was statistically significant(P<0.05). Before treatment, compared with frequent and prolonged seizures patients in both groups, there was no statistically significant difference(P>0.05);after treatment, the number of attacks in the two groups was significantly reduced, and the duration of attacks was shortened. The observation group was superior to the control group, the difference was statistically significant(P<0.05). Conclusion Carbamazepine combined with valproate sodium in the treatment of frontal lobe epilepsy can play a synergistic role in inhibiting abnormal discharge of lesions, improve the anxiety and depression symptoms, relieve the clinical manifestations, and reduce the rate of seizures, and the brain damage.
作者 宋杨 SONG Yang(Department of Neurology,14th Floor,Geriatrics Center,the 4th People's Hospital of Shenyang,Shenyang 110034,China)
出处 《中国药物经济学》 2020年第9期53-55,60,共4页 China Journal of Pharmaceutical Economics
关键词 卡马西平 丙戊酸钠 额叶癫痫 脑损伤 Carbamazepine Sodium valproate The frontal lobe epilepsy Cerebral injury
  • 相关文献

参考文献11

二级参考文献65

  • 1Ghodke-Puranik Y, Thom CF, Lamba JK,eZ al. Valproic acidpathway: pharmacokinetics and pharmacodynamics [J]. Phar-macog Genom,2013,23(4): 236-241.
  • 2Amini-Shirazi N,Ahmadkhaniha R,Shadnia al. Determi-nation of VP A and its two important metabolites in iranian o-verdosed patients[J]. Inter J Pharmacol, 2010,6(6) :854-862.
  • 3Dupuis RE’Lichtman SN, Pollack GM. Acute valproic acid o-verdose : Clinical course and pharmacokinetic disposition of val-proic acid and Metabolites [J〕. Drug Saf,1990,5(1): 65-71.
  • 4Loscher W,Nau Htetal. Valproic acid; metabolite concentra-tions in plasma and brain,antic- onvulsant activity and effectson GABA metabolism during subacute treatment in mice[J].Arch Int Pharmacodyn Ther,1982,257(1) :20-31.
  • 5Andrew S, Davison, Anna M, etal. The consequences of val-proate overdose [J]. Clinical Chemistry, 2011,57(9): 1233-1238.
  • 6Mock CM, Schwetschenau KH. Levocarnitine for valproicacid-induced hyperammonemic encephalopathy [ J ]. Am JHealth Syst Pharm, 2012,69(21) : 35-39.
  • 7Lewis C,Deshpande A, Tesar GE,et al. Valproate-inducedhyperainnionemic encephalopathy : a brief review[J]. Curr MedResOpin,2012,28(6); 1039-1042.
  • 8Otoul C, De Smedt H, Stockis A. Lack of pharmacokinetic in-teraction of LEV on carbamazepine,valproic acid, topiramate,and lamotrigine in children with epilepsy[J]. Epilepsia, 2007,48(11):2111-2115.
  • 9Roh SY, Jang HS, Jeong EH, et al. Valproic acid-induced hy-perammonemic encephalopathy promoted by levetiracetam [J].J Epilepsy Res, 2014,4(2) :82-84.
  • 10Jayakumar S, Thomas KH. Assessment of the role of in situGenerated (E)-2,4 diene-valproic acid in the toxicity of valpro-ic acid and (E )-2-ene-valproic acid in sandwich-cultured rathepatocytes[J]. Toxicol Appl Pharmacol, 2012, 264 (3) : 413-422.

共引文献106

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部